Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ) is pleased to announce it has signed an exclusive license agreement with Sonic Healthcare USA, a Division of Sonic Healthcare Ltd (OTCMKTS: SKHHY) for the use and commercialization of the Company's PromarkerD test for diabetic kidney disease in the United States. Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ) is pleased to announce it has signed an exclusive license agreement with Sonic Healthcare USA, a Division of Sonic Healthcare Ltd (OTCMKTS: SKHHY) for the use and commercialization of the Company's PromarkerD test for diabetic kidney disease in the United States. Under the agreement, Sonic Healthcare USA will be offering PromarkerD to physicians and healthcare systems through its client engagement teams across the US...